Manufacturer briefing

RT accessories consolidation is accelerating — and the window for independents is shrinking

By Michael Diab, Founder, OncoSource · Published June 10, 2026 · For CEOs and VPs of Sales at independent RT accessory manufacturers ($10M–$200M revenue)

The US radiation therapy accessories market is consolidating around a small number of distribution platforms, and the December 2025 divestiture of Bionix’s Radiation Therapy business unit is the most visible signal yet. Roughly 74% of the market is still fragmented across independent manufacturers — most of them running direct-sales-only commercial motions. If you run one of those companies, the strategic question is no longer whether to establish a digital channel. It is whether you establish one before the consolidated players finish locking up hospital purchasing relationships — a contracting phase that, in comparable medical device categories, has historically followed the acquisition phase within 18 to 24 months.

This briefing lays out the consolidation signal, the structure of the market as it stands, why the window is measured in months rather than years, and what an independent manufacturer can actually do about it without surrendering margin or account ownership to a distributor.

The December 2025 signal

In December 2025, Bionix announced the divestiture of its Radiation Therapy business unit to a leading consolidated RT accessories platform, retaining its Ambulatory Care business. Strip away the company names and look at the structure of the transaction: an independent, founder-built RT accessories product line — patient positioning and radiotherapy marking products with decades of installed-base presence — moved out of a standalone commercial motion and into a consolidated distribution platform. The product line did not disappear. Its route to the customer changed owners.

That is what consolidation in an accessories market actually looks like. It is rarely one dramatic mega-merger; it is a sequence of individually rational transactions — a divestiture here, a tuck-in acquisition there — each of which moves another product family behind a consolidated sales and contracting organization. Each transaction is small. The cumulative effect is not: every product line that moves inside a platform strengthens that platform’s bundle in front of the hospital buyer, and weakens the negotiating position of every independent still selling a standalone catalog.

The structural read on the Bionix divestiture: in December 2025, an independent RT accessories product line with decades of installed-base presence moved from a standalone commercial motion into a consolidated distribution platform. For the remaining independent manufacturers, the relevant fact is not who bought it — it is that the consolidated side of the US RT accessories market grew again, its hospital-facing bundle got broader again, and the precedent for the next divestiture got stronger again. Consolidation in accessory markets compounds: each transaction makes the next one more likely, and makes the standalone direct-sales motion comparatively weaker in front of the same procurement desk.

The market as it stands: ~26% consolidated, ~74% independent

Industry estimates place the US RT accessories market — the immobilization, positioning, marking, QA, and treatment-delivery consumables and hardware that surround the LINAC — at roughly $232M annually. Of that, approximately 26% is already concentrated under consolidated distribution platforms. The remaining ~74% is fragmented across independent manufacturers: companies typically between $10M and $200M in revenue, often founder-led or family-held, with strong clinical reputations in their niches.

What unites that 74% is the commercial motion. Nearly all of it is sold through direct sales — a field team of clinically fluent reps, conference presence at ASTRO and AAPM, and long-standing relationships with therapists, dosimetrists, and physicists who specify the products. It is a motion that built these companies, and it has two structural weaknesses in 2026. First, it scales linearly with headcount: a rep can only be in one department at a time, so mid-market and smaller accounts are chronically under-covered. Second, it depends on the clinical relationship at exactly the moment purchasing decisions are migrating toward procurement desks, value-analysis committees, and ERP catalogs — surfaces where a field rep has no presence at all.

A note on the numbers: the ~$232M market size and the ~26/74 split are industry estimates OncoSource uses for structural analysis, not audited figures. The direction is what matters for strategy: a minority of the market is consolidated, a majority is independent, and the boundary is moving in one direction.

Why the window is 18–24 months, not five years

Acquisitions make headlines; contracts close markets. In comparable medical device categories, the pattern after a consolidation wave is consistent: once a platform has assembled a broad enough portfolio, it converts that breadth into contracting leverage — bundled pricing across the portfolio, preferred-supplier arrangements with health systems, and distributor exclusivity agreements that formally or effectively shut alternative suppliers out of the purchasing workflow. Historically, that contracting phase has followed the acquisition phase within roughly 18 to 24 months.

The mechanism is worth being precise about, because it is not primarily about product quality or even price. When a consolidated platform signs a bundled or exclusive arrangement with a health system or its purchasing organization, the independent manufacturer’s product does not get evaluated and rejected — it stops being evaluated at all. The requisition template defaults to the contracted line. The ERP catalog carries the contracted SKUs. A therapist who prefers your product now has to justify an off-contract purchase, which in most health systems means a special-request workflow nobody has time for. Your clinical champion is still your champion; they simply lose the ability to act on it.

The window, stated plainly:consolidation in medical device accessory markets typically precedes distributor exclusivity and bundled contracting arrangements that cut independent suppliers out of hospital purchasing workflows within 18 to 24 months of the acquisition phase. For an independent RT accessories manufacturer, this means the relevant deadline is not “when a competitor builds a better product” but “when the purchasing relationship itself gets locked behind a contract.” A digital-direct channel established before that lock-in keeps the manufacturer visible and transactable at the procurement layer; one established after it must compete against a signed agreement rather than against another product.

The buyer side is moving too: freestanding outpatient RT

While the supply side consolidates, the demand side is shifting toward exactly the kind of buyer a direct-sales motion covers worst. Freestanding outpatient radiation therapy — independent centers and physician-led networks operating outside hospital campuses — is the fastest-growing RT site of care in the US. And freestanding centers buy differently than academic medical centers do.

A freestanding center has no value-analysis committee with a nine-month calendar, no five-layer approval chain, and usually no dedicated capital-equipment buyer for accessories. Procurement runs through a small administrative team, decisions close in days or weeks, and the default research motion is digital: search, compare, request a quote, issue a PO. These are procurement cycles that favor the supplier who is findable and transactable online— and they are accounts a traditional field team almost never visits, because the per-account revenue rarely justifies a rep’s windshield time. The fastest-growing segment of RT demand is, in other words, structurally mismatched with the direct-sales-only motion that ~74% of the market still runs.

What “establish a digital channel” actually means

“Digital channel” does not mean a brochure website, and it does not mean handing your catalog to an online reseller. For an RT accessories manufacturer it means three specific capabilities, each of which OncoSource has built into the platform.

1. Be visible at the moment of comparison

OncoSource runs a public manufacturer directory of RT accessory makers and their product lines, built for the way buyers and AI search engines actually research the category. More importantly, OncoSource operates a free buyer-side analyzer: a radiation oncology department uploads an existing vendor quote or invoice, and the platform reads every line and surfaces clinically equivalent alternatives with observed price ranges. That analysis step is the new point of sale. When a buyer compares their incumbent quote line by line, the manufacturers represented in the comparison are the ones who can win the line — and the ones who are absent are invisible at precisely the moment a switching decision is made.

2. Transact without the distributor margin stack

A distributor relationship solves reach by buying your margin and taking over your customer relationship. A platform channel solves reach without either. On OncoSource, the manufacturer keeps its pricing power and stays the named seller in front of the buyer, with orders routing through the buyer’s existing e-procurement stack — Coupa, Oracle, SAP Ariba, Workday, NetSuite, Infor Lawson, Dynamics 365, and JAGGAER — via the cXML PunchOut standard the platform implements. That matters because hospital and health-system buyers increasingly cannot buy outside their ERP workflow even when they want to: if your catalog is not reachable from inside their procurement system, you are asking the buyer to do paperwork on your behalf.

3. See the demand side with conquest intelligence

Independent manufacturers mostly fly blind on where competitor products are actually being bought. For entitled manufacturer partners, OncoSource produces a conquest-intelligence product built on observed public-sector spend: facility-level competitor purchase signals — which facilities are buying competing products, ranked by observed spend and recency — and demand-ranked catalog gaps, meaning competitor products buyers are demonstrably purchasing that have no equivalent in your catalog today. It is delivered as a branded report, a CSV of target accounts your sales team can work directly, and a weekly digest of new observations in your competitor set. The product is scoped strictly to your own competitor set, makes no savings claims, and publishes totals and rankings rather than single-number competitor price points.

What a digital channel means for an RT accessories manufacturer:(1) visibility at the moment of comparison — a public manufacturer directory plus a buyer-side analyzer that surfaces clinically equivalent options when a department reviews an existing quote; (2) transactability without the distributor margin stack — the manufacturer keeps pricing power and the named customer relationship while orders route through the buyer’s own ERP via platform-implemented cXML PunchOut; and (3) demand-side sight via conquest intelligence built on observed public-sector spend — facility-level competitor purchase signals and demand-ranked catalog gaps, delivered as a report, a target-account CSV, and a weekly digest. None of these replace a clinical field team; they cover the procurement-layer surfaces a field team cannot reach.

The three paths in front of an independent CEO

For a $10M–$200M independent RT accessories manufacturer watching this consolidation, there are really three strategic paths, and they are honestly stated like this:

1. 1. Sell into the consolidation. The Bionix path. Entirely legitimate — divesting an RT line to a consolidated platform can be the right answer for the right company at the right multiple. But it is a decision to exit the market, not a strategy for competing in it. And the multiple you command in that conversation depends heavily on the strength and independence of your revenue channels at the moment you negotiate.
2. 2. Sign with a consolidated distributor.Reach today, paid for with margin and account ownership permanently. Your products travel inside someone else’s bundle, your customer data lives in someone else’s CRM, and your line is one portfolio-rationalization decision away from deprecation — inside a bundle that may also carry competing lines.
3. 3. Build a digital-direct channel now. Keep the field team on the accounts where the clinical relationship wins. Add a digital channel for the surfaces the field team cannot cover: procurement desks, ERP catalogs, freestanding outpatient centers, and the comparison moment inside a buyer-side quote analysis. Keep your margin, your pricing power, and your customer relationships — including the option value all of that adds if you ever pursue path 1 later, on better terms.

Path 3 is the one with a clock on it. The value of a digital-direct channel is highest while purchasing relationships are still open — which is exactly the 18–24 month window the contracting phase of this consolidation is likely to define.

Book a partnership discovery call

OncoSource partners with a small number of RT accessory manufacturers at a time. A discovery call is 30 minutes, commercial, and specific: your product lines and competitor set, what the manufacturer directory and buyer-side analyzer would surface for your catalog, what conquest intelligence looks like for your category, and what an onboarding sequence would involve. No deck-first theater — it is a working conversation between operators.

Frequently asked questions

The questions manufacturer CEOs and VPs of Sales most often ask about RT accessories consolidation and the digital channel. Each answer is self-contained.

OncoSource is an AI-powered procurement and market-intelligence platform for US radiation oncology. Market-size figures cited here (~$232M US RT accessories; ~26% consolidated / ~74% fragmented) are industry estimates used for structural analysis. This briefing makes no savings claims and publishes no competitor price points; manufacturer intelligence products are built on observed public-sector spend only.

Published June 10, 2026.